Tuberc Respir Dis.  2013 Jan;74(1):37-40.

Erlotinib Induced Trichomegaly of the Eyelashes

Affiliations
  • 1Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea. jsryu@inha.ac.kr
  • 2Department of Dermatology, Inha University College of Medicine, Incheon, Korea.

Abstract

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.

Keyword

Receptor, Epidermal Growth Factor; Erlotinib; Lung Neoplasms; Eyelashes; Physiological Effects of Drugs

MeSH Terms

Adenocarcinoma
Cosmetics
Eyelashes
Female
Humans
Lung
Lung Neoplasms
Physiological Effects of Drugs
Protein-Tyrosine Kinases
Quinazolines
Receptor, Epidermal Growth Factor
Erlotinib Hydrochloride
Cosmetics
Physiological Effects of Drugs
Protein-Tyrosine Kinases
Quinazolines
Receptor, Epidermal Growth Factor

Figure

  • Figure 1 Chest computed tomography scan showed a mass lesion on the upper lobe of the right lung.

  • Figure 2 Chest computed tomography scans before and after two months of erlotinib monotherapy. Pulmonary nodules noted on both lungs (arrows) were nearly disappeared in two months after the commencement of erlotinib.

  • Figure 3 Trichomegaly of eyelashes developed in two months after the commencement of erlotinib.


Reference

1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002. 20:110–124.
2. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004. 22:3238–3247.
3. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006. 1:1040–1041.
4. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 2007. 23:65–66.
5. Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004. 151:1111–1112.
6. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005. 23:165–174.
7. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008. 26:3460–3462.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. 45:228–247.
9. Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 2005. 16:1711–1712.
10. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001. 144:1169–1176.
11. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009. 4:684–688.
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr